Israel’s War Costs Seen Rising $7.5 Billion on Gaza City Assault

Israel's war costs are projected to rise by an additional 25 billion shekels ($7.5 billion) by year-end, driven by the Gaza City assault. This new expenditure, equivalent to over 1% of Israel's GDP, adds to the existing 204-billion-shekel military tally for the conflict, which has expanded to include Lebanon, Iran, Syria, and Yemen, with primary spending on reservists' salaries, ammunition, and missile interceptors.

Analysis

Israel's fiscal position is set to deteriorate further as the war in Gaza escalates, with the planned assault on Gaza City projected to add 25 billion shekels ($7.5 billion) in military costs by year-end. This new expenditure, representing over 1% of the nation's GDP, compounds an already substantial 204-billion-shekel military bill for a conflict that has been ongoing for nearly two years and has expanded regionally to include Lebanon, Iran, Syria, and Yemen. The identified cost drivers—namely reservists' salaries, ammunition, and missile interceptors—indicate that these are direct, operational expenses rather than long-term capital investments. This significant, unbudgeted fiscal shock points to increased pressure on the national budget, likely necessitating greater sovereign debt issuance and potentially impacting investor confidence in the country's economic stability amidst a protracted and widening geopolitical conflict.

Key Decisions for Investors

• Given the substantial new fiscal burden, which equates to over 1% of GDP, investors should anticipate heightened pressure on Israel's sovereign credit profile and potential for depreciation in the Israeli shekel (ILS).
• The expected increase in government borrowing to fund the war suggests caution for holders of Israeli government bonds, as greater debt issuance could lead to higher yields and lower bond prices.
• The diversion of significant economic resources to a widening conflict poses a headwind for the broader Israeli equity market, warranting a reassessment of exposure, particularly to companies reliant on domestic economic health.